Technical Bulletins-COVID

COVID-19

• COVID 2024-2025 Guidance
• FDA Approves and Authorizes for Emergency Use Updated COVID-19 Vaccines and De-authorizes Administration of 2023-2024 COVID-19 Vaccines 
• 2023-2024 COVID-19 Vaccine Recommendations
• Updated COVID-19 Infection Prevention and Control Guidance for Health Care Personnel
• FDA Ends Monovalent mRNA Authorization and Simplifies Use of Bivalent COVID-19 Vaccines
• Bivalent COVID-19 Vaccines Now Authorized for Expansion in 6 months and Older
• Discontinuation of Reporting COVID-19 Negative Laboratory Results
• Adverse Event Reporting Following COVID-19 Vaccination
• Bivalent COVID-19 Vaccines Now Authorized for individuals 6 months of Age and Older
• Novavax COVID-19 Vaccine, Adjuvanted Booster Now Authorized for 18+
• Bivalent COVID-19 Booster Vaccine Recommended for 5 Years and Older
• Updated Infection Prevention and Control Recommendations for Health Care Personnel During the Coronavirus Disease (COVID-19) Pandemic
• Novavax COVID-19 Vaccine, Adjuvanted, Now Recommended by CDC for 12+ Years
• Updated Guidance: What To Do When Exposed to COVID-19
• Bivalent COVID-19 Booster Vaccine Recommended for 12 Years and Older
• Updated Guidance: Isolation and Precautions for People with COVID-19
• Novavax COVID-19 Vaccine, Adjuvanted Authorized for Emergency Use Authorization
• Moderna COVID-19 Vaccine Approved for Children and Adolescents 6 – 17 years
• Pediatric COVID-19 Vaccines Recommended for Children Aged 6 months – 5 years
• Pfizer-BioNTech COVID-19 Vaccine Booster Dose for Children 5-11 Years
• COVID-19 Vaccine Additional Booster Dose Recommendations
• Updates to COVID-19 Laboratory Reporting Requirements
• Updated Interim Clinical Considerations for COVID-19 Vaccine Use
• Mask Mitigation Requirements for Licensed Health Care Facilities
• Updated Quarantine Guidance - Jan. 31, 2022
• Developing and maintaining written plans that balance access to care, staffing shortages and infection control
• Updated Quarantine Guidance - Jan. 18, 2022
• COVID-19 Vaccine Updated Booster Dose Recommendations
• Update to COVID-19 Point of Care Antigen Testing in Community Settings
• Public Health Considerations for COVID-19 At-Home Test Kit
• Updated COVID-19, Influenza and RSV
• Updated Quarantine Guidance
• Updated Guidance for Discontinuation of COVID-19 Isolation
• Preferential Recommendations for mRNA COVID-19 Vaccines
  • Recomendaciones Preferentes para vacunas ARNm contra COVID-19
• COVID-19 Vaccine Booster Doses for 16-17-year-olds
  • Dosis de refuerzo de la vacuna Covid-19 para jóvenes de 16-17 años
• COVID-19 Vaccine Booster Dose Recommendations for Adults and Emergency Use Instructions
  • Boletín Técnico de la Programa de Inmunización del Estado de Nevada - Recomendaciones de dosis de refuerzo de la vacuna Covid-19 para adultos e instrucciones de uso en caso de emergencia
• Clinical considerations for administering Pfizer-BioNTech COVID-19 vaccine to children ages 5-11 years
• COVID Vaccine Booster Doses for Janssen/Johnson & Johnson (J&J) and Moderna
• Clinical Laboratory Submission to State and Local Public Health Laboratories
• Update: COVID-19 Point of Care Antigen Testing in Community Settings
• COVID-19, Influenza and Respiratory Syncytial Virus (RSV)
• Pfizer-BioNTech COVID-19 Vaccine Booster Recommendations
• Quarantine new admits and readmissions regardless of vaccination status in nursing homes and residential facilities
  • Poner en cuarentena a los nuevos ingresos y a los reingresos, independientemente del estado de vacunacion en las residencias de ancianos e instalaciones residenciales.
• Updated Tuberculosis (TB) Testing Recommendations Around COVID-19 Vaccinations
  • Recomendaciones actualizadas para las pruebas de tuberculosis (TB) en torno a las vacunas COVID-19
• Regulatory Updates for COVID-19 Vaccines – U.S. Food and Drug Administration Approves Licensure of the Pfizer-BioNTech COVID-19 Vaccine
• Recommendations for COVID-19 Vaccination for People Who are Pregnant or Breastfeeding
  • Recomendaciones para la vacuna contra COVID-19 para Personas Embarazadas o Mujeres bajo lactancia
• Additional mRNA COVID-19 Dose Recommended for Moderately and Severely Immunocompromised Individuals
  • Dosis adicional de ARNm contra COVID-19 recomendada para individuos con inmunodepresión moderada o grave
• COVID-19 Data Reporting Requirement for Skilled Nursing Facilities
• Updated Tuberculosis (TB) Testing Interim Recommendations Around COVID-19 Vaccinations
• COVID-19 Sequencing Update - Clinical Laboratories to Submit all Positive SARS-CoV-2 Samples to the Nevada State Public Health Laboratory
  • Actualización de la secuenciación de COVID-19 - Los laboratorios clínicos deben enviar todas las muestras positivas de SARS-CoV-2 al laboratorio de salud pública del estado de Nevada
• ACIP Discussions on Myocarditis Post-COVID 19 Vaccination and Potential Need for COVID-19 Booster Doses
  • Debates del ACIP sobre la miocarditis después de la vacunación con COVID 19 y la posible necesidad de dosis de refuerzo de COVID-19
• Monitoring Reports of Myocarditis Post-COVID-19 Vaccination
  • Informes de Seguimiento sobre Miocarditis Post Vacuna COVID-19
• Public Health Considerations for COVID-19 At-Home Test Kits
  • Consideraciones de Salud Publica para los Kits de Prueba Casera para COVID-19
• COVID-19 Vaccines May Now Be Coadministered
  • Las Vacunas contra COVID-19 Ahora Se Pueden Coadministrar
• Clinical considerations for administering Pfizer-BioNTech COVID-19 vaccine to adolescents ages 12-15 years
• Updated CMS and CDC Guidance for Visitation
• Resuming Use of J&J COVID 19 Vaccine
  • Reanudar el uso de la Vacuna J&J COVID 19
• Adverse Event Reporting Following COVID-19 Vaccination
  • Reportar Evento Adverso después de la recibir la Vacuna COVID-19
• Overall Quarantine Guidance
  • Orientación General sobre Cuarentena
• Storage and Handling of COVID-19 Vaccines
• Pause in Administration of Johnson & Johnson (Janssen) COVID-19 Vaccine
• CDC Interim Public Health Recommendations for Fully Vaccinated Individuals
• Implementation Considerations for the Janssen (Johnson & Johnson) COVID-19 Vaccine
  • Consideraciones de Implementación para la Vacuna contra COVID-19 de Janssen (Johnson & Johnson) COVID-19
• Quarantine Guidance for Vaccinated Persons
  • Orientación de Cuarentena para Personas Vacunadas
• Guidance on Vaccine Access for Nevadans with Underlying Health Conditions
  • Actualización a la Orientación del Programa de Inmunización del Estado de Nevada sobre Acceso a la Vacuna para las personas de Nevada con condiciones de salud subyacentes
• Placement of patients/residents who have been vaccinated against COVID-19 or who have had COVID-19 and have recovered
  • Colocación de pacientes/ residentes que han sido vacunados contra COVID-19 o que han tenido COVID-19 y han recuperado
• Moderna Vaccine Lot 41L20A and higher incidence of adverse reactions
• COVID-19 Point of Care Antigen Testing
  • Novedad: Pruebas de Antígeno en el Punto de Atención para COVID-19
• Requirement for Hospitals to Report Ban on Medically Necessary Procedures
  • Requisito para Hospitales Informar sobre la Prohibición de Procedimientos Medicamente Necesarios
• CDC Updated Guidance for Reducing Quarantine Period for Contacts of Persons with COVID-19 Infection
• Guidance for Discontinuation of COVID-19 Isolation
  • Orientación sobre la suspensión del aislamiento de COVID-19
• REMOVAL OF DIRECTIVE to Discontinue the Use of Antigen Testing in Skilled Nursing Facilities Until Further Notice
• COVID-19 Laboratory Reporting Requirements
• COVID-19 Point of Care Testing (8/28/2020)
• Guidelines for Discontinuation of In-Home Isolation and Transmission-Based Precautions among Hospitalized Patients with COVID-19
• Require Immediate Reporting of COVID-19 Test Results to the Nevada Division of Public and Behavioral Health
• Multisystem Inflammatory Syndrome in Children (MIS-C) and Required Reporting for MIS-C
  • Síndrome Inflamatorio Multisistémico en Niños (MIS-C) y Reportaje Requerido para MIS-C
• Pharmacists and Medical Laboratory Testing Under the PREP Act - issued 06-02-2020
  • Farmacéuticos y Prueba Médica de Laboratorio Bajo la Ley PREP
• Expansion of COVID-19 Testing Criteria - issued 05-05-2020
  • Ampliación de los Criterios de Prueba para COVID-19
  • Laboratory Testing Frequently Asked Questions
• Updated Testing Criteria for COVID-19 - issued 04-20-2020
• Non-Physician Practitioners and Home Health Orders - issued 04-17-2020
  • Practicantes No- Médicos y Órdenes de Atención Medica en el Hogar
• Interim Guidance on Alternative, Improvised and Homemade Facemasks - issued 04-03-2020
• Guidance for Health Care Personnel with Potential Exposure to COVID-19 Patients - issued 04-01-2020
• Visitors' Guide to Health Care Facilities - issued 03-30-2020
• COVID-19 Message to Employers - issued 03-27-2020
• Home Health Personnel and Coronavirus Disease 2019 (COVID-19) - issued 03-23-2020
• Updated Interim Testing Criteria for COVID-19 - issued 03-20-2020
• Interim Guidelines for Discontinuation of In-Home Isolation and Transmission-Based Precautions among Hospitalized Patients with COVID-19 - issued 03-17-2020
• COVID-19 Practices and Processes for Nevada Health Facilities - issued 03-16-2020
• Reporting of Extraordinary Occurrence of Illness - issued 03-05-2020
• CDC Updated Interim Infection Prevention & Control Recommendations for Patients with Known or Patients Under Investigation for 2019 Novel Coronavirus in a Healthcare Setting - issued 01-31-2020
• Novel Coronavirus general information - issued 01-24-2020